Gland Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Gland Pharma Limited Pharmaceutical Export Portfolio Dataset — 29 Products, $262.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Gland Pharma Limited — Pharmaceutical Exporter Profile (2026) | 29 Products, $262.0M Trade | TransData Nexus

Gland Pharma Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $262.0M Total Trade · DGFT Verified

Gland Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $262.0M across 29 products in 15 therapeutic categories. Based on 5,302 verified export shipments from Indian Customs (DGFT) records, Gland Pharma Limited is the #1 Indian exporter in 4 products including Heparin, Enoxaparin, Syringe. Top exports include Heparin ($83.5M), Enoxaparin ($58.2M), Syringe ($42.6M).

Gland Pharma Limited — Export Portfolio & Destination Treemap

Gland Pharma Limited pharmaceutical export portfolio — 29 products across 15 therapeutic categories. Source: Indian Customs (DGFT).

Who is Gland Pharma Limited? — Company Overview & Market Position

Gland Pharma Limited, established in 1978, is a prominent Indian pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Headquartered in Hyderabad, Telangana, India, the company has expanded its global footprint, exporting to over 60 countries, including the United States, Europe, Canada, Australia, and New Zealand.

The company operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a global pharmaceutical major. As of March 13, 2026, Gland Pharma's stock is listed on the National Stock Exchange of India under the ticker symbol GLAND, with a market capitalization of approximately $3.0 billion USD. The company employs over 4,300 individuals, reflecting its significant presence in the pharmaceutical manufacturing sector.

What Does Gland Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Heparin$83.5M 2Enoxaparin$58.2M

Product Portfolio — Top 29 by Export Value

Gland Pharma Limited exports 29 pharmaceutical products across 15 therapeutic categories. Market leader (#1 exporter) in 4 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Heparin	Cardiovascular	$83.5M	1,669	10.8%	1
2	Enoxaparin	Cardiovascular	$58.2M	1,164	11.8%	1
3	Syringe	Medical Devices & Diagnostics	$42.6M	853	17.2%	1
4	Ketorolac	Analgesics & Antipyretics	$20.3M	405	9.1%	1
5	Sodium	Nutritional Supplements	$11.4M	229	3.2%	2
6	Ondansetron	Gastrointestinal	$9.5M	216	4.2%	5
7	Vancomycin	Antibiotics	$8.3M	167	5.9%	3
8	Insulin	Diabetes & Endocrine	$4.5M	92	5.3%	4
9	Furosemide	Diuretics	$2.9M	74	2.8%	9
10	Tobramycin	Antibiotics	$2.6M	52	4.5%	4
11	Magnesium	Vitamins & Supplements	$2.3M	46	0.6%	14
12	Ertapenem	Advanced Antibiotics	$2.3M	45	1.3%	3
13	Meropenem	Advanced Antibiotics	$2.3M	45	0.7%	9
14	Zinc	Vitamins & Supplements	$1.6M	33	1.3%	7
15	Levothyroxine	Diabetes & Endocrine	$1.6M	31	1.0%	8
16	Voriconazole	Advanced Antifungals	$1.2M	24	2.4%	5
17	Doxycycline	Antibiotics	$1.1M	23	1.0%	9
18	Fluorouracil	Oncology	$1.1M	26	9.0%	4
19	Azithromycin	Antibiotics	$1.1M	21	0.6%	12
20	Oxaliplatin	Advanced Oncology	$1.0M	20	2.1%	5
21	Cisplatin	Oncology	$530.1K	11	4.1%	6
22	Carboplatin	Oncology	$500.0K	10	0.7%	4
23	Posaconazole	Advanced Antifungals	$300.0K	6	0.3%	3
24	Metoclopramide	Gastrointestinal	$286.0K	20	1.3%	9
25	Ephedrine	Respiratory & OTC	$250.0K	5	1.1%	8
26	Bortezomib	Advanced Oncology	$200.0K	4	0.9%	10
27	Diazepam	CNS & Psychiatric	$200.0K	4	2.7%	3
28	Irinotecan	Oncology	$200.0K	4	0.5%	9
29	Melphalan	Advanced Oncology	$150.0K	3	1.2%	3

Gland Pharma Limited exports 29 pharmaceutical products across 15 therapeutic categories with a total export value of $262.0M. The company is the #1 Indian exporter in 4 products: Heparin, Enoxaparin, Syringe, Ketorolac. The top category is Cardiovascular (54.1% of portfolio), followed by Medical Devices & Diagnostics (16.3%), indicating a concentrated portfolio with the top 5 products accounting for 82.4% of total export value.

Gland Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Gland Pharma operates seven manufacturing facilities across India, comprising four for finished formulations and three for active pharmaceutical ingredients (APIs). These facilities are strategically located in Hyderabad and Visakhapatnam, Andhra Pradesh, ensuring efficient production and distribution capabilities.

The company's manufacturing plants are equipped with state-of-the-art technology and adhere to current Good Manufacturing Practices (cGMP). They specialize in the production of sterile injectables, oncology, and ophthalmic products, focusing on complex injectables such as New Chemical Entity-1s (NCE-1s), First-to-File products, and 505(b)(2) filings.

3Key Leadership

Gland Pharma's leadership team is headed by Executive Chairman Mr. Srinivas Sadu, who has been instrumental in steering the company's strategic direction. The Chief Executive Officer (CEO) is Mr. Shyamakant Giri, who joined the company in 2025. The Chief Financial Officer (CFO) is Mr. Ravi Shekhar Mitra, who has been with the company since 2024.

Other key executives include Mr. Satnam Singh Loomba, Chief Operating Officer, and Mr. Shriniwas P. Dange, Head of Investor Relations. The Board of Directors comprises independent directors such as Mr. Udo Johannes Vetter, Mr. Essaji Goolam Vahanvati, and Ms. Naina Lal Kidwai, ensuring a diverse and experienced governance structure.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Gland Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Gland Pharma has established a strong presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. In May 2024, the company received approval from the U.S. Food and Drug Administration (FDA) for its generic Edaravone injection, a treatment for amyotrophic lateral sclerosis. In April 2024, the FDA approved Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial, further expanding Gland Pharma's portfolio in the U.S. market.

In June 2025, the company received an Establishment Inspection Report from the FDA for its JNPC facility in Visakhapatnam, India, indicating compliance with FDA standards. Gland Pharma's adherence to international regulatory standards, including those of the European Medicines Agency (EMA) and the Therapeutic Goods Administration (TGA) in Australia, underscores its commitment to quality and compliance in these markets.

2Emerging Markets

Gland Pharma has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of high-quality injectable formulations to meet diverse healthcare needs.

3Geographic Strategy

Gland Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Gland Pharma's facilities are registered with the U.S. FDA, and the company has a history of approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings. The receipt of an Establishment Inspection Report from the FDA for its JNPC facility in Visakhapatnam in June 2025 indicates compliance with FDA standards. The company's commitment to quality and regulatory compliance is further demonstrated by its adherence to current Good Manufacturing Practices (cGMP) across its manufacturing facilities.

2WHO & EU GMP

Gland Pharma's manufacturing facilities comply with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. This compliance ensures that the company's products meet international quality standards, facilitating access to global markets and reinforcing its reputation as a reliable supplier of injectable formulations.

3CDSCO & Indian Regulatory

In India, Gland Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company also possesses export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets. These regulatory approvals underscore Gland Pharma's compliance with Indian pharmaceutical regulations and its capability to meet global standards.

Gland Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Gland Pharma operates in a competitive landscape with key players such as Sun Pharmaceutical Industries Ltd., IPCA Laboratories Ltd., and Emcure Pharmaceuticals Ltd. While Gland Pharma holds a leading position in the production of injectable formulations, particularly in complex injectables, it faces competition from these established companies in overlapping therapeutic categories. The company's focus on high-quality, affordable products and its global distribution network provide a competitive edge in the market.

2Key Differentiators

Gland Pharma's key differentiators include its specialization in complex injectables, a robust research and development pipeline, and a strong commitment to quality and regulatory compliance. The company's diverse product portfolio across various therapeutic segments and delivery systems, coupled with its focus on sterile injectables, oncology, and ophthalmics, distinguishes it in the pharmaceutical industry.

3Strategic Position

Gland Pharma's current strategic direction focuses on the development and manufacturing of generic injectables, with an emphasis on complex formulations and contract development and manufacturing organization (CDMO) services. The company's future outlook includes expanding its presence in regulated and emerging markets, enhancing its product portfolio, and leveraging its manufacturing capabilities to meet global healthcare needs.

Buyer Due Diligence Brief — Evaluating Gland Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Gland Pharma has a strong track record in the pharmaceutical industry, with a consistent export volume of $262.0 million USD across 5,302 shipments from 2022 to 2026. The company's reliability is evidenced by its leading market positions in products such as Heparin, Enoxaparin, Syringes, and Ketorolac, with market shares of 10.8%, 11.8%, 17.2%, and 9.1%, respectively. These indicators reflect Gland Pharma's capacity to meet global demand and its commitment to quality and consistency.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's facilities are registered with the U.S. FDA.

WHO-GMP Certification: Ensure manufacturing facilities comply with WHO Good Manufacturing Practices.

EU GMP Certification: Verify adherence to European Union Good Manufacturing Practices.

Frequently Asked Questions — Gland Pharma Limited

How many pharmaceutical products does Gland Pharma Limited export from India?

Gland Pharma Limited exports 29 pharmaceutical products across 15 therapeutic categories. The top exports are Heparin ($83.5M), Enoxaparin ($58.2M), Syringe ($42.6M), Ketorolac ($20.3M), Sodium ($11.4M). Total export value is $262.0M.

What is Gland Pharma Limited's total pharmaceutical export value?

Gland Pharma Limited's total pharmaceutical export value is $262.0M, based on 5,302 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Gland Pharma Limited the #1 Indian exporter?

Gland Pharma Limited is the #1 Indian exporter in 4 products: Heparin (10.8% market share), Enoxaparin (11.8% market share), Syringe (17.2% market share), Ketorolac (9.1% market share).

What therapeutic categories does Gland Pharma Limited cover?

Gland Pharma Limited exports across 15 therapeutic categories. The largest are Cardiovascular (54.1%, 2 products), Medical Devices & Diagnostics (16.3%, 1 products), Analgesics & Antipyretics (7.7%, 1 products).

Get Full Gland Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.